SD-OCT Guided Treatment of Fungal Chorioretinitis

NCT ID: NCT04947592

Last Updated: 2021-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-15

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fungal Chorioretinitis is a vision threatening condition.The investigators evaluate the efficacy of SD-OCT role in the treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination and SD-OCT was done.Procedure included oral fluconazole treatment 1 tablet once for 14 days

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fungal Retinitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

fungal chorioretinitis OCT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluconazole 150 mg

fluconazole 150 MG once daily for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- fungal chorioretinitis

Exclusion Criteria

* vitritis
* other macular lesion
* macular scar
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tarek Roshdy mohamed Mahgoub ELhamaky

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

TAREK ELHAMAKY

Role: PRINCIPAL_INVESTIGATOR

Benha University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

INMC

Abu Dhabi, , United Arab Emirates

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Arab Emirates

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

TAREK R ELHAMAKY, MD

Role: CONTACT

Phone: 0503207889

Email: [email protected]

TAREK ELHAMAKY

Role: CONTACT

Phone: 0503207889

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

TAREK R ELHAMAKY, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Hamaky13

Identifier Type: -

Identifier Source: org_study_id